20 August 2026
Moderna’s stock retreated on Thursday following a record-setting jump a day earlier, cutting more than $18 billion from the company’s market valuation, as investors appeared to pull back after the biotech giant reported breakthrough trial results for a cancer vaccine. READ MORE: https://www.forbes.com/sites/tylerrou...
